# Epizyme, Inc. clinical trials: 21 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 21 trials with Epizyme, Inc. as lead sponsor, 0 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Epizyme, Inc.: 21 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/company/epizyme-inc

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 21
- Recruiting or not yet: 0
- Read on: November 19, 2026

## Trials

The 21 newest of 21, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| October 5, 2023 | NCT06068881 | A Study to Assess Efficacy and Safety of Oral Tazemetostat in Adult Participants With Relapsed/Refractory Follicular Lymphoma That Does Not... | Epizyme, Inc. | Phase 2 | Withdrawn | Follicular Lymphoma, Refractory Follicular Lymphoma | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06068881) |
| January 25, 2022 | NCT05205252 | A Study of Tazemetostat in Combination With Various Treatments in Participants With Blood Cancer. | Epizyme, Inc. | Phase 1/2 | Withdrawn | Relapsed Hematologic Malignancy, Refractory Hematologic Malignancy | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05205252) |
| November 16, 2021 | NCT05121103 | A Study of the Safety, Tolerability and Effectiveness of EZM0414 (IPN60210) Investigative Product in Participants With Relapsed/Refractory... | Epizyme, Inc. | Phase 1 | Terminated | Multiple Myeloma, Refractory, Diffuse Large B-Cell Lymphoma, Diffuse Large B Cell Lymphoma Refractory, Multiple Myeloma... | 13 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05121103) |
| February 21, 2021 | NCT04762160 | SYMPHONY-2, A Trial to Examine Combination of Tazemetostat With Rituximab in Subjects With Relapsed/Refractory Follicular Lymphoma | Epizyme, Inc. | Phase 2 | Terminated | Follicular Lymphoma | 5 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04762160) |
| September 3, 2020 | NCT04537715 | Effects of Itraconazole and Rifampin on the Blood Tazemetostat Levels | Epizyme, Inc. | Phase 1 | Completed | All Malignancies, Advanced Malignancies, Hematologic Malignancy, Solid Tumor, Follicular Lymphoma (FL), Non-Hodgkin... | 42 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04537715) |
| January 27, 2020 | NCT04241835 | A Study to Compare the Blood Levels and Safety of Tazemetostat in Participants With Advanced Cancer and Moderate/Severe Liver Impairment to... | Epizyme, Inc. | Phase 1 | Terminated | Hepatic Impairment, Advanced Malignant Solid Tumor | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04241835) |
| January 13, 2020 | NCT04225429 | Tazemetostat Expanded Access Program for Adults With Epithelioid Sarcoma | Epizyme, Inc. | Not applicable | No longer available | Epithelioid Sarcoma | Not listed | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04225429) |
| January 13, 2020 | NCT04224493 | A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus... | Epizyme, Inc. | Phase 3 | Active not recruiting | Relapsed/Refractory Follicular Lymphoma, Follicular Lymphoma, Refractory Follicular Lymphoma | 599 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04224493) |
| December 19, 2019 | NCT04204941 | Tazemetostat in Combination With Doxorubicin as Frontline Therapy for Advanced Epithelioid Sarcoma | Epizyme, Inc. | Phase 1 | Terminated | Advanced Soft-tissue Sarcoma, Advanced Epithelioid Sarcoma | 25 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04204941) |
| November 27, 2019 | NCT04179864 | A Study of Tazemetostat With Enzalutamide or Abiraterone/Prednisone in Participants With Advanced Prostate Cancer | Epizyme, Inc. | Phase 1/2 | Terminated | Metastatic Prostate Cancer, Metastatic Castration-resistant Prostate Cancer | 102 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04179864) |
| March 14, 2019 | NCT03874455 | Tazemetostat Expanded Access Program for Adults With Solid Tumors | Epizyme, Inc. | Not applicable | No longer available | Epithelioid Sarcoma (Ex-US Only), Spindle Cell Sarcoma, Sinonasal Carcinoma, Small Cell Carcinoma of the Ovary... | Not listed | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03874455) |
| February 12, 2019 | NCT03837678 | Epithelioid Sarcoma Natural History Study | Epizyme, Inc. | Observational | Completed | Epithelioid Sarcoma | 74 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03837678) |
| January 23, 2017 | NCT03028103 | Open-Label, Multicenter, Two-Part, Phase 1 Study to Characterize Effects of a Moderate CYP3A Inhibitor on PK of Tazemetostat, Effects of... | Epizyme, Inc. | Phase 1 | Completed | Diffuse Large B Cell Lymphoma, Primary Mediastinal Lymphoma, Mantle Cell Lymphoma, Advanced Solid Tumor, Marginal Zone... | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03028103) |
| January 5, 2017 | NCT03010982 | Open-Label, Multi-Center, Two-Part, Ph1 Study to Characterize the PKs of an Intravenous Micro-Dose of \[14C\]-Tazemetostat (EPZ 6438) and the... | Epizyme, Inc. | Phase 1 | Completed | Diffuse Large B Cell Lymphoma, Primary Mediastinal Lymphoma, Mantle-Cell Lymphoma, Follicular Lymphoma, Marginal Zone... | 3 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03010982) |
| August 23, 2016 | NCT02875548 | A Study to Assess Long-term Safety of Tazemetostat in Adult Participants of All Ages With Any Disease Treated With Tazemetostat in a... | Epizyme, Inc. | Phase 1/2 | Terminated | Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), Synovial Sarcoma, Epithelioid Sarcoma (ES)... | 58 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02875548) |
| August 9, 2016 | NCT02860286 | Study of the EZH2 Inhibitor Tazemetostat in Malignant Mesothelioma | Epizyme, Inc. | Phase 2 | Completed | Mesothelioma, BAP1 Loss of Function | 74 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02860286) |
| November 11, 2015 | NCT02601950 | A Study of Tazemetostat in Adult Participants With Soft Tissue Sarcoma | Epizyme, Inc. | Phase 2 | Completed | Malignant Rhabdoid Tumors (MRT), Rhabdoid Tumors of the Kidney (RTK), Atypical Teratoid Rhabdoid Tumors (ATRT)... | 267 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02601950) |
| November 11, 2015 | NCT02601937 | EZH2 Inhibitor Tazemetostat in Pediatric Subjects With Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma | Epizyme, Inc. | Phase 1 | Completed | Rhabdoid Tumors, INI1-negative Tumors, Synovial Sarcoma, Malignant Rhabdoid Tumor of Ovary | 109 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02601937) |
| May 20, 2014 | NCT02141828 | A Phase 1 Dose Escalation and Expanded Cohort Study of EPZ-5676 in the Treatment of Pediatric Patients With Relapsed/Refractory Leukemias... | Epizyme, Inc. | Phase 1 | Completed | Leukemia, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Acute Leukemias | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02141828) |
| July 12, 2013 | NCT01897571 | Study of Tazemetostat as Single Agent in Solid Tumors or B-cell Lymphomas and in Combination With Prednisolone in DLBCL | Epizyme, Inc. | Phase 1/2 | Completed | B-cell Lymphomas (Phase 1), Advanced Solid Tumors (Phase 1), Diffuse Large B-cell Lymphoma (Phase 2), Follicular... | 400 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01897571) |
| September 12, 2012 | NCT01684150 | A Phase 1, Open-Label, Dose-Escalation & Expanded Cohort, Continuous IV Infusion, Multi-center Study of the Safety, Tolerability,PK & PD of... | Epizyme, Inc. | Phase 1 | Completed | Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, Myeloproliferative Disorders | 51 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01684150) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 9 |
| Phase 1/2 | 4 |
| Phase 2 | 4 |
| Phase 3 | 1 |
| Not applicable | 2 |
| Observational | 1 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 10 |
| Terminated | 6 |
| Withdrawn | 2 |
| No longer available | 2 |
| Active not recruiting | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Lymphoma, Follicular | 7 |
| Lymphoma, Large B-Cell, Diffuse | 6 |
| Sarcoma | 6 |
| Sarcoma, Synovial | 5 |
| Mesothelioma | 3 |
| Rhabdoid Tumor | 3 |
| Hematologic Neoplasms | 2 |
| Lymphoma, Non-Hodgkin | 2 |
| Lymphoma, Mantle-Cell | 2 |
| Lymphoma, B-Cell, Marginal Zone | 2 |
| Leukemia | 2 |
| Leukemia, Myeloid, Acute | 2 |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2 |
| Lymphoma, B-Cell | 1 |
| Chondrosarcoma | 1 |
| Carcinoma, Renal Cell | 1 |
| Mesothelioma, Malignant | 1 |
| Desmoplastic Small Round Cell Tumor | 1 |
| Prostatic Neoplasms | 1 |
| Myelodysplastic Syndromes | 1 |
| Myeloproliferative Disorders | 1 |
| Neoplasms | 1 |
| Multiple Myeloma | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Pediatric endocrinology practices in the United States](https://specstream.ai/data/businesses/pediatric-endocrinology-practices/united-states)
- [South African restaurants in the United States](https://specstream.ai/data/businesses/south-african-restaurants/united-states)
- [3D printing companies in the United States](https://specstream.ai/data/businesses/3d-printing-companies/united-states)
- [Buffet restaurants in the United States](https://specstream.ai/data/businesses/buffet-restaurants/united-states)
- [Eastern European restaurants in the United States](https://specstream.ai/data/businesses/eastern-european-restaurants/united-states)
- [Home network installers in the United States](https://specstream.ai/data/businesses/home-network-installers/united-states)
